KLRAKailera Therapeutics, Inc.

🇺🇸 US
14.24
USD
Analysis Scores
Lothien Robustness Score?
49/100
Moderate
Neden bu skor?
Damodaran ?
23/100
DCF hesaplanamadı (faaliyet kârı veya nakit akışı eksik)
Dalio Risk ?
82/100
Piotroski ?
N/A
Yetersiz çeyrek verisi: 4 mevcut, en az 5 gerekli
Graham ?
Negatif HBK
Company is loss-making (EPS = -1.8292 TL) — Graham formula requires positive earnings
Active Metric?
1/4
Confidence?
48%
Lothien Robustness Summary
22/100
Lothien Sağlamlık: Çok Zayıf (22/100)
Temel göstergelerin çoğu olumsuz. Lothien sağlamlık skoru düşük seviyede. | Kısa Vade: Olumsuz | Uzun Vade: Olumsuz | Pozitif: 1 | Negatif: 4 | Nötr: 1
Net Zarar
Son çeyrekte -$96M zarar açıklandı. Yatırımcı dikkatli olmalı.
Kâr Stabil
Net kâr bir önceki çeyreğe göre fazla değişmedi (%+14.1). İstikrarlı seyir.
Yıllık Kâr Geriledi
Geçen yılın aynı dönemine göre net kâr %-141.4 düştü. Uzun vadede endişe verici.
4 Çeyrek Üst Üste Düşüş
Son 4 çeyrek üst üste kâr düşüyor. Aşağı trend endişe verici. Sonraki çeyreğe dikkat.
Güçlü Likidite
Cari oran 21.84x — kısa vadeli borçları rahat karşılıyor.
Negatif ROE
ROE: %-26.6. Şirket özsermayesini eritiyor.

Data date 2026-11-10 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-11-10
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Çok Yüksek
144 days
Annual Volatility ?
%72.5
VaR 95% ?
%7.83
daily max loss
VaR 99% ?
%10.94
daily max loss
CVaR 95% ?
%8.97
expected loss (tail)
Max Drawdown ?
%61.5
17.04.2026 → 08.10.2026
Skewness ?
0.44
Parametrik%7.83
Historik%6.59
Cornish-Fisher%7.12
Return Distribution
Valuation
Potential?
+63.9%
ROIC ?
-29.8%
Debt Cycle?
Early Expansion
Balance Sheet Analysis? Q2026/9
Net kâr çeyreklik %+14.1 artarak -95.7M USD oldu
Yıllık net kâr %-141.4 geriledi
Cari oran güçlü: 21.84x — yükümlülükler rahat karşılanıyor
Nakit %-18.2 azaldı → 106.5M USD
İşletme nakit akışı negatif: -133.7M USD
ROE negatif: %-9.3 — zarar var
ROA düşük: %-8.8
Toplam varlıklar %-10.7 küçüldü → 1.1B USD
Özkaynak %-7.8 azaldı → 1.0B USD
İşletme kârı negatif: -106.3M USD — faaliyet zararı
Net işletme sermayesi pozitif: 877.6M USD
Son 6 çeyrek ardışık zarar
Fiyat TRAMA-99 hafif altında: %-3.9
Direnç seviyesi: TRAMA-99 = 14.82 USD
Likit varlık ağırlığı yüksek: Dönen varlıklar toplam varlıkların %85'i
Fundamental & Technical Analysis
Profitability
ROE - Return on Equity (TTM) %-26.6
ROE %-26.6 — negative return on equity.
Valuation
P/B Ratio 1.78x Sector: 4.55x
PD/DD 1.78x — sector median's (4.55x) well below. Cheap relative to book value.
Indebtedness
Current Ratio 21.84x
Current ratio 21.84x — current assets are 2x short-term liabilities. Very healthy liquidity.
Debt / Equity 0.01x
Low leverage — majority of assets financed by equity.
Interest Coverage -396.2x
Interest coverage -396.2x — critical level. Risk of difficulty in interest payments.
Growth
Net Profit Growth (YoY) %-141.4
Loss %141.4 increased — losses deepening.
Score Explanations
Lothien Robustness
49/100
Moderate robustness (49/100). Valuation and risk criteria give mixed signals. Detailed review recommended.
Moderate
Potential
+63.9%
Plus %63.9 expected value (23.16) vs current price comparison. 1/4 valuation models could be calculated. Model confidence %48.
Components: P/B target: 32.95
Damodaran Valuation
23/100
Very Weak
Dalio Risk Analysis
82/100
Low debt risk (82/100). Interest coverage ratio -396.2x — weak, fragile.
Leverage: 100/100 | Debt Service: 100/100 | Quality: 26/100
ROIC - Return on Capital
%-29.8
ROIC (%-29.8) cost of capital (12.3%) below → destroying value.
WACC: %12.3
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
—
Graham Intrinsic Value
—
Company is loss-making (EPS = -1.8292 TL) — Graham formula requires positive earnings
⚖️ Sector Comparison
P/B Ratio
1.78x vs 4.55x
Compared to sector %61 cheaper (by book value)
ROIC vs WACC
%-29.8 vs %12.3 WACC
ROIC 42.1 bps below cost of capital
↔
TRAMA-99 Trend — Near TRAMA
Price (14.24), TRAMA-99 line (14.82) at close levels (%-3.9). Important decision zone — breakout direction will determine the trend.
Price:: 14.24
TRAMA: 14.82
Difference: %-3.9
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
▲ içeriden alım · ▼ içeriden satım · ★ katalizör (haber-sezgisel) · ■ 13D aktivist · ■ 13G pasif — SEC Form 4 ~2 gün gecikmeli, yalnız yönetici/direktör/%10+ sahip; katalizör = haber-sezgisel; 13D/G = %5+ pay bildirimi ~5 iş günü gecikmeli.
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
Kurumsal Holdings — 13F (çeyreklik) ?

İçeriden Alım-Satım Akışı

Kim aldı, kim sattı, ne kadar

KLRA — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.